12 Month Price Forecast For BLCO
Distance to BLCO Price Forecasts
BLCO Price Momentum
🤔 Considering Bausch + Lomb (BLCO)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 3:34 AM UTC
BLCO Analyst Ratings & Price Targets
Based on our analysis of 16 Wall Street analysts, BLCO has a consensus that is bullish. The median price target is $21.50, with forecasts ranging from $18.00 to $26.00. Currently, there are 8 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
With BLCO currently trading at $17.07, the median price forecast suggests a 26.0% upside. The most optimistic forecast comes from Larry Biegelsen at Wells Fargo, projecting a 52.3% upside, while Pito Chickering at Deutsche Bank provides the most conservative target, suggesting a 5.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BLCO Analyst Consensus
BLCO Price Target Range
Latest BLCO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BLCO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 31, 2024 | Citigroup | Joanne Wuensch | Buy | Maintains | $24.00 |
| Oct 31, 2024 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $23.00 |
| Oct 31, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $26.00 |
| Oct 22, 2024 | RBC Capital | Douglas Miehm | Outperform | Maintains | $23.00 |
| Oct 15, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Upgrade | $25.00 |
| Oct 1, 2024 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $19.00 |
| Sep 23, 2024 | Stifel | Thomas Stephan | Hold | Maintains | $19.00 |
| Sep 23, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $22.00 |
| Sep 16, 2024 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Aug 5, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $19.00 |
| Aug 5, 2024 | RBC Capital | Douglas Miehm | Outperform | Reiterates | $20.00 |
| Aug 1, 2024 | Deutsche Bank | Pito Chickering | Hold | Maintains | $18.00 |
| Aug 1, 2024 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Aug 1, 2024 | RBC Capital | Douglas Miehm | Outperform | Reiterates | $20.00 |
| Jul 10, 2024 | Raymond James | Gary Nachman | Outperform | Initiates | $19.00 |
| Jul 2, 2024 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $15.50 |
| May 6, 2024 | Morgan Stanley | Patrick Wood | Overweight | Upgrade | $18.00 |
| May 2, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $20.00 |
| May 1, 2024 | Needham | David Saxon | Hold | Reiterates | $0.00 |
Stocks Similar to Bausch + Lomb Corporation
The following stocks are similar to Bausch + Lomb based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bausch + Lomb Corporation (BLCO) Financial Data
Bausch + Lomb Corporation has a market capitalization of $6.96B with a P/E ratio of -23.1x. The company generates $4.68B in trailing twelve-month revenue with a -7.9% profit margin.
Revenue growth is +18.8% quarter-over-quarter, while maintaining an operating margin of +5.4% and return on equity of -5.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Bausch + Lomb Corporation (BLCO) Company Overview
About Bausch + Lomb Corporation
Provides comprehensive eye health products and services.
Bausch + Lomb generates revenue through three main segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment sells contact lenses and related care products, while the Pharmaceuticals segment markets both proprietary and generic medications for various eye conditions. The Surgical segment focuses on medical devices and surgical instruments used in eye surgeries, with sales made through direct sales forces and independent distributors.
Founded in 1853 and headquartered in Vaughan, Canada, Bausch + Lomb operates globally in multiple countries, making it a significant player in the eye health market. It is a subsidiary of Bausch Health Companies Inc.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
13,000
CEO
Mr. Brenton L. Saunders J.D.
Country
Canada
IPO Year
2022
Website
www.bausch.comBausch + Lomb Corporation (BLCO) Latest News & Analysis
U.S. stock futures rose, with Dow futures increasing by over 150 points on Tuesday.
Rising U.S. stock futures indicate positive market sentiment, potentially leading to increased investor confidence and buying activity in the stock market.
Bausch + Lomb Corporation (NYSE:BLCO) will hold its Q3 2024 earnings call on October 30, 2024, at 8:00 AM ET, featuring executives including the CEO and CFO.
Bausch + Lomb's Q3 earnings call signals financial performance insights, impacting stock valuation and investor sentiment on growth and profitability prospects.
Bausch + Lomb (BLCO) reported its quarterly performance for September 2024, with key metrics available for comparison against Wall Street estimates and prior year results.
Comparing Bausch + Lomb's quarterly performance to estimates and prior year results helps assess growth potential and market positioning, influencing investment decisions and stock valuation.
Bausch + Lomb (BLCO) reported Q3 earnings of $0.17 per share, surpassing the Zacks estimate of $0.16, but down from $0.22 per share year-over-year.
Bausch + Lomb's earnings beat estimates, indicating stronger performance than anticipated, but a year-over-year decline may raise concerns about growth sustainability.
Bausch + Lomb (BLCO) shares rose after reports that Blackstone (BX) and TPG (TPG) are exploring a potential acquisition of the eyecare company.
The potential buyout by Blackstone and TPG may drive Bausch + Lomb's share price higher, indicating strong investor interest and confidence in the company's value.
Why Bausch + Lomb Stock Soared by Over 7% on Monday
3 months agoThe company experienced a busy and eventful day, indicating potential developments or changes that may impact its operations or market performance.
A busy day for the company may indicate significant developments or changes, potentially impacting stock performance, investor sentiment, and future growth prospects.
Frequently Asked Questions About BLCO Stock
What is Bausch + Lomb Corporation's (BLCO) stock forecast for 2025?
Based on our analysis of 16 Wall Street analysts, Bausch + Lomb Corporation (BLCO) has a median price target of $21.50. The highest price target is $26.00 and the lowest is $18.00.
Is BLCO stock a good investment in 2025?
According to current analyst ratings, BLCO has 8 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $17.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for BLCO stock?
Wall Street analysts predict BLCO stock could reach $21.50 in the next 12 months. This represents a 26.0% increase from the current price of $17.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bausch + Lomb Corporation's business model?
Bausch + Lomb generates revenue through three main segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment sells contact lenses and related care products, while the Pharmaceuticals segment markets both proprietary and generic medications for various eye conditions. The Surgical segment focuses on medical devices and surgical instruments used in eye surgeries, with sales made through direct sales forces and independent distributors.
What is the highest forecasted price for BLCO Bausch + Lomb Corporation?
The highest price target for BLCO is $26.00 from Larry Biegelsen at Wells Fargo, which represents a 52.3% increase from the current price of $17.07.
What is the lowest forecasted price for BLCO Bausch + Lomb Corporation?
The lowest price target for BLCO is $18.00 from Pito Chickering at Deutsche Bank, which represents a 5.4% increase from the current price of $17.07.
What is the overall BLCO consensus from analysts for Bausch + Lomb Corporation?
The overall analyst consensus for BLCO is bullish. Out of 16 Wall Street analysts, 8 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $21.50.
How accurate are BLCO stock price projections?
Stock price projections, including those for Bausch + Lomb Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
